The desire to eat runs continuously, draining energy for everything else
Obesity is now recognized as a complex, multifactorial chronic disease linked to adipose tissue dysfunction, not personal failure or lack of willpower. Semaglutida (Wegovy) and similar GLP-1 medications show 20% weight reduction, with some patients achieving 28% loss comparable to bariatric surgery results.
- European Obesity Congress 2026 in Istanbul gathered over 3,000 medical professionals
- Semaglutida (Wegovy) achieved 20% weight reduction, with some patients reaching 28% loss comparable to bariatric surgery
- SELECT study showed 20% reduction in heart attack, stroke, and all-cause mortality in patients with prior cardiovascular events
- 84.4% of weight lost was fat; only 15.6% was muscle mass
- Obesity now recognized as chronic adipose tissue disease, not personal failure
European obesity experts shift focus from willpower to chronic disease biology, emphasizing adipose tissue dysfunction and personalized treatment strategies including semaglutide therapy.
In Istanbul this spring, more than three thousand medical professionals gathered for the European Obesity Congress to announce something that sounds simple but represents a fundamental shift in how medicine understands one of the world's most pressing health crises: obesity is not a failure of willpower. It is a disease.
For decades, the condition was framed as a personal shortcoming—eat less, exercise more, try harder. The stigma that followed kept people away from doctors and made treatment adherence nearly impossible. But the science has moved on. Obesity, specialists now agree, is a chronic, complex, multifactorial illness rooted in the dysfunction of adipose tissue—the body's fat stores. When that tissue swells or loses its proper function, it releases inflammatory substances and redistributes itself in anatomically dangerous places. The result is a cascade of metabolic and hormonal disruptions that no amount of willpower can overcome alone.
Dr. Juliana Mosciulsky, who coordinates the Obesity and Diabetes Committee for Argentina's Diabetes Society and attended the Istanbul congress, put it plainly: obesity deserves the same clinical attention as diabetes, hypertension, or heart disease. The condition touches every medical specialty. Endocrinologists, cardiologists, psychiatrists, gynecologists, nephrologists, hepatologists—all were present in Istanbul because obesity cuts across all of them. It can lead to more than two hundred associated complications, from type 2 diabetes to osteoarthritis to sleep disorders to cardiovascular disease.
The congress introduced a more precise terminology: adiposopathy, or chronic adipose tissue disease. This shift matters because it moves the focus away from a single number on a scale toward understanding individual patterns—what doctors now call phenotypes. Where the fat accumulates determines the risk. Visceral fat, which deposits deep in the abdomen and around internal organs, carries the highest metabolic and cardiovascular danger. Other patterns of fat distribution create different problems: functional impairment, joint damage, vascular complications. The diagnosis itself is being refined. While body mass index remains useful, doctors now complement it with measurements of abdominal circumference and analysis of fat distribution to identify who faces the greatest risk before complications develop.
The pharmaceutical breakthrough presented at the congress centered on semaglutida, marketed as Wegovy, which mimics the body's natural GLP-1 hormone. When someone eats, the body releases GLP-1 to signal fullness. Semaglutida extends and amplifies that signal, helping people perceive satiety, pause, think, decide, reduce portions, choose better. The Step Up study showed that higher doses—7.2 milligrams—produced weight reductions up to twenty percent in patients who had not responded well to standard doses. Some patients achieved reductions near twenty-eight percent, comparable to bariatric surgery. Critically, eighty-four percent of the weight lost was fat; only fifteen-point-six percent was muscle, a ratio far more favorable than other weight-loss methods.
The SELECT study, presented as a centerpiece of the congress, examined semaglutida's effect on cardiovascular outcomes in people with obesity and prior heart events. The medication reduced the incidence of non-fatal heart attack, non-fatal stroke, and death from all causes by twenty percent, with no significant difference between men and women. This finding reframes semaglutida not merely as a weight-loss drug but as a cardiac medication—mandatory, Mosciulsky emphasized, for patients with prior cardiovascular events. The drug reduces the risk of fatal recurrence and improves daily life for people living with obesity and its complications.
But the congress also surfaced something less quantifiable: the patient's experience. The AUX-STEP1 study tracked how people's priorities shifted during treatment. Most began hoping only to lose weight. As treatment progressed, they discovered they valued something else more: the quieting of constant food thoughts, the ability to make decisions without compulsion, the capacity to sustain new habits. For people with obesity, the desire to eat runs continuously, intrusively, draining energy for everything else. When that noise quiets, other things become possible—like exercise, which many had avoided due to stigma and functional limitation. Weight loss opened a door.
The congress message was clear: weight reduction must be accompanied by adequate protein intake and individualized, progressive physical activity focused on strength and resistance. With proper nutrition and exercise planning, muscle mass can be preserved entirely—a point especially vital for women approaching or in menopause, when estrogen decline increases visceral fat and metabolic risk, and for older adults facing natural muscle loss. The evidence showed that current pharmacological treatments work equally well across all menopausal stages in women, opening new prevention possibilities. The obesity congress of 2026 demonstrated that treating this disease demands science, empathy, and strategies tailored to each person. The integration of effective medications, multidisciplinary support, and recognition of the social and psychological weight people carry represents a new era in addressing an illness that affects millions worldwide.
Citações Notáveis
Obesity is a chronic, very complex, multicausal and recurrent disease that requires the same attention as any other chronic disease, like diabetes, hypertension, or cardiovascular disease.— Dr. Juliana Mosciulsky, Obesity and Diabetes Committee coordinator, Argentine Diabetes Society
When we see a decrease in visceral adipose tissue, we know we are gaining health.— Dr. Juliana Mosciulsky
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that obesity is now called a disease of adipose tissue rather than a failure of willpower?
Because language shapes how we treat people. When you call something a character flaw, patients hide. They don't go to doctors. They don't try treatments. When you call it a disease, you open the door to medicine.
But people do need to change their eating and exercise habits. Doesn't calling it purely biological let them off the hook?
No. It actually makes change possible. When someone understands their hunger signals are genuinely disrupted—not that they lack discipline—they can work with medication to quiet that noise. Then exercise becomes feasible instead of something they avoid out of shame.
The semaglutida results sound remarkable. But are these drugs just a shortcut?
They're not a shortcut. They're a tool that addresses the biological problem directly. The drug doesn't do the work for you. It lets you think clearly enough to do the work yourself—to choose smaller portions, to move your body, to build new habits.
What surprised you most from the congress?
How much the patients themselves changed the conversation. They said weight loss wasn't even their main goal anymore. What mattered was that constant food obsession finally stopping. That mental relief was worth more than the numbers on the scale.
Why does where the fat sits matter so much?
Visceral fat—the deep abdominal kind—is metabolically toxic. It inflames your organs, raises your blood pressure and cholesterol, damages your heart. Losing that specific fat means you're actually gaining health, not just losing weight.
So a personalized approach means different treatments for different people?
Exactly. One person's obesity might be primarily visceral and cardiovascular. Another's might be functional—joint pain, mobility. The treatment strategy changes. The diagnosis has to be precise before the medicine can be.